PCSK9抑制剂对ST段抬高型急性心肌梗死PCI后炎症水平和心室重构的影响  

Effect of PCSK9 inhibitors on inflammation levels and ventricular remodeling after PCI in ST-elevation acute myocardial infarction

作　　者：张卫丰 马海龙 张金玲 ZHANG Weifeng;MA Hailong;ZHANG Jinling(Emergency Center of Qingdao Central Hospitalof Rehabilitation University(Qingdao Central Hospital),Qingdao 266043,China)

机构地区：[1]康复大学青岛中心医院(青岛市中心医院)急救中心,山东青岛266043

出　　处：《实用医学杂志》2024年第15期2142-2147,共6页The Journal of Practical Medicine

基　　金：青岛市医药卫生科研指导项目(编号:2022-wjzd057)。

摘　　要：目的探讨PCSK9抑制剂对急性ST段抬高型心肌梗死经皮冠状动脉介入治疗术(PCI)后心室重构及炎症因子的影响。方法选择2021年4月至2023年7月在青岛市中心医院急救中心就诊的行经皮冠脉介入手术治疗的220例急性ST段抬高型心肌梗死患者随机分为两组,对照组110例采取常规治疗,PCSK9i组110例在常规治疗基础上应用PCSK9抑制剂,比较治疗前后左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)及左室射血分数(LVEF)和甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)、C反应蛋白(CRP)、白细胞介素6(IL-6),肿瘤坏死因子α(TNF-α)。比较主要不良心血管事件(MACE)(包括再次心肌梗死发生率、严重心律失常率、再度心衰发生率、心血管死亡发生率)。结果两组经过6个月的治疗及随访,PCSK9i组治疗后LVEDD(mm)、LVESD(mm)和TG(mmol/L)、TC(mmol/L)、LDL-C(mmol/L)、CRP(mg/L)、TNF-α(pg/mL)、JL-6(ng/mL)均低于对照组,差异有统计学意义[(51.32±5.84)vs.(54.43±2.91);(34.88±2.69)vs.(36.96±3.19);(1.41±0.61)vs.(2.13±1.26);(3.53±1.06)vs.(3.98±0.93);(0.95±0.36)vs.(1.79±0.27);(5.18±1.92)vs.(7.69±2.61);(36.43±9.41)vs.(57.79±14.43);(17.4±6.68)vs.(28.55±8.92),均P<0.01],PCSK9i组LVEF(%)、HDL-C(mmol/L)高于对照组,差异有统计学意义[(46.69±3.63)vs.(41.34±3.42),P<0.05;(1.35±0.29)vs.(1.29±0.27),P<0.01]。PCSK9i组MACE发生率明显低于对照组(5.2%vs.13.6%,P<0.05)。结论ST段抬高型急性心肌梗死患者PCI后应用PCSK9抑制剂可以更好的降低血脂,稳定冠状动脉斑块,减轻心肌梗死后的局部及循环炎症反应,改善心肌梗死后心室不良重构、抑制心室重构、降低主要MACE总发生率,值得推广使用。Objective To investigate the effect of PCSK9 inhibitors on the level of inflammation and ventricular remodeling after PCI in ST-elevation acute myocardial infarction.Methods A total of 220 patients with acute ST-segment elevation myocardial infarction who received percutaneous coronary artery intervention in the Emergency Center of Qingdao Central Hospital from April 2021 to July 2023 were randomly divided into two groups,110 patients in the control group were treated with conventional treatment,and 110 patients in the PCSK9i group were treated with PCSK9 inhibitors on the basis of conventional treatment.Compared before and after treatment left ventricular endsystolic diameter(LVESD)and left ventricular ejection fraction(LVEF)and triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),total cholesterol(TC).C-reactive protein(CRP),interleukin 6(IL-6),tumor necrosis factorα(TNF-α).The incidence of major adverse cardiovascular events(MACE)(including myocardial infarction,recurrence of heart failure,malignant arrhythmia,and cardiovascular death)was compared.Results After 6 months of treatment and follow-up,LVEDD(mm),LVESD(mm),TG(mmol/L),TC(mmol/L),LDL-C(mmol/L),CRP(mg/L),TNF-α(pg/mL)and JL-6(ng/mL)after PCSK9i treatment were significantly lower than those in the control group,and the difference was statistically significant[(51.32±5.84)vs.(54.43±2.91);(34.88±2.69)vs.(36.96±3.19);(1.41±0.61)vs.(2.13±1.26);(3.53±1.06)vs.(3.98±0.93);(0.95±0.36)vs.(1.79±0.27);(5.18±1.92)vs.(7.69±2.61);(36.43±9.41)vs.(57.79±14.43);(17.4±0.68)vs.(28.55±8.92),All P<0.01],and the LVEF(%)and HDL-C(mmol/L)in the PCSK9i group were higher than patients in the control group,and the difference was statistically significant[(46.69±3.63)vs.(41.34±3.42),P<0.05,(1.35±0.29)vs.(1.29±0.27),P<0.01].The incidence of MACE events in the PCSK9i group was obviously lower than patients in the control group(5.2%vs.13.6%,P<0.05).Conclusion The application of PCSK9 inhibitors after PCI in pati

关 键 词：ST段抬高型急性心肌梗死 心血管事件 PCSK9抑制剂 炎症因子 心室重构 

分 类 号：R541.4[医药卫生—心血管疾病]